Quick Answer
Cyclerion Therapeutics, Inc. reported Revenue (ASC 606) of $2.30 million for fiscal year 2020.
Cyclerion Therapeutics, Inc. Revenue (ASC 606) — Annual History
| Fiscal Year | Revenue (ASC 606) | YoY Change |
|---|---|---|
| 2020 | $2.30M | -49.1% |
| 2019 | $4.51M | — |
Quarterly Revenue (ASC 606)
| Quarter Ending | Revenue (ASC 606) | YoY | QoQ |
|---|---|---|---|
| September 30, 2020 | $400.0K | -71.4% | -46.6% |
| June 30, 2020 | $749.0K | -54.0% | -26.1% |
| March 31, 2020 | $1.01M | — | -27.5% |
| September 30, 2019 | $1.40M | — | -14.1% |
| June 30, 2019 | $1.63M | — | — |
- Cyclerion Therapeutics, Inc. showed a decrease of -49.1% in Revenue (ASC 606) compared to the prior fiscal year.
- Over the 2019–2020 period, Cyclerion Therapeutics, Inc.’s revenue (asc 606) has declined by 49.1% (from $4.51 million to $2.30 million).
- The most recent figure is from Cyclerion Therapeutics, Inc.’s fiscal year 2020 report (Form 10-K), filed with the SEC on February 25, 2021.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: